Deferred Tax Assets, Valuation Allowance in USD of Mersana Therapeutics, Inc. from Q4 2016 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Mersana Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q4 2016 to Q4 2024.
  • Mersana Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $263M, a 9.76% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Mersana Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $263M +$23.4M +9.76% 31 Dec 2024 10-K 03 Mar 2025
Q4 2023 $239M +$48.9M +25.6% 31 Dec 2023 10-K 03 Mar 2025
Q4 2022 $191M +$60.5M +46.5% 31 Dec 2022 10-K 28 Feb 2024
Q4 2021 $130M +$52.7M +68.1% 31 Dec 2021 10-K 28 Feb 2023
Q4 2020 $77.4M +$28.5M +58.3% 31 Dec 2020 10-K 28 Feb 2022
Q4 2019 $48.9M -$5.05M -9.36% 31 Dec 2019 10-K 26 Feb 2021
Q4 2018 $53.9M +$21.3M +65.5% 31 Dec 2018 10-K 28 Feb 2020
Q4 2017 $32.6M +$6.61M +25.4% 31 Dec 2017 10-K 08 Mar 2019
Q4 2016 $26M 31 Dec 2016 10-K 28 Mar 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.